Focus: Acrivon Therapeutics is a checkpoint inhibitor-focused oncology biotech based in Watertown, MA, currently in early clinical stages with a lean pipeline.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Best suited for early-career clinical or biostatistics professionals seeking oncology expertise and meaningful project ownership, but carry significant financial and milestone risk compared to better-capitalized peers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Acrivon Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Acrivon Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
RA Capital boosts Acrivon (ACRV) stake to 28.8% after ATM share buy - Stock Titan
RA Capital boosts Acrivon (ACRV) stake to 28.8% after ATM share buy Stock Titan
RA Capital funds add 3,888,888 Acrivon (ACRV) shares at $1.80 - Stock Titan
RA Capital funds add 3,888,888 Acrivon (ACRV) shares at $1.80 Stock Titan
Acrivon (ACRV) Chief Legal Officer has 558 shares withheld for RSU taxes - Stock Titan
Acrivon (ACRV) Chief Legal Officer has 558 shares withheld for RSU taxes Stock Titan
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
New Acrivon employee gets stock options for 111,150 shares - Stock Titan
New Acrivon employee gets stock options for 111,150 shares Stock Titan
[SCHEDULE 13D/A] Acrivon Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
[SCHEDULE 13D/A] Acrivon Therapeutics, Inc. Amended Major Shareholder Report Stock Titan
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles